Ponatinib
CAS 943319-70-8 4 FDA-DMF suppliersSmall Molecule
Overview
Ponatinib is a small molecule active pharmaceutical ingredient (ChEMBL CHEMBL1171837).
Patent & exclusivity (US)
Per the FDA Orange Book (4 approved US products), the latest listed US patent on Ponatinib expires 12 Dec 2033 and exclusivity 19 Mar 2031. Generic API sourcing typically opens up once these lapse.
Chemical identity
- IUPAC name
- 3-(2-imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-N-[4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl]benzamide
- Canonical SMILES
- CC1=C(C=C(C=C1)C(=O)NC2=CC(=C(C=C2)CN3CCN(CC3)C)C(F)(F)F)C#CC4=CN=C5N4N=CC=C5
- InChIKey
- PHXJVRSECIGDHY-UHFFFAOYSA-N
Ready to Accelerate Your
Discovery Workflow?
Find, vet, and source drug-manufacturing partners faster — with FDA compliance screening built in. Start free for 14 days.